
|Videos|September 20, 2021
Dr. Staskin discusses counseling patients on vibegron for OAB
Author(s)Urology Times staff
“Patients want to see an improvement. They want a drug that obviously is efficacious and safe, where the side effects are low,” says David Staskin, MD.
Advertisement
In this video, David Staskin, MD, discusses the takeaways associated with the findings from the study, “Vibegron for the treatment of patients with dry overactive bladder: A subgroup analysis from the EMPOWUR trial,” presented at the 2021 American Urological Association annual meeting. Staskin is a director of the Center for Male and Female Pelvic Health and associate professor of urology at Tufts University, Boston, Massachusetts.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA provides guidance on development pathway for testosterone therapy for women
2
Pearls & Perspectives: Leadership and Prostate Cancer, with Mark L. Gonzalgo, MD, PhD, MBA
3
Treatment Selection in Advanced Prostate Cancer
4
Pedro Freitas, MD, on consolidative surgery vs prolonged systemic therapy in MIBC
5






